跳至主要内容
临床试验/NCT01618435
NCT01618435Unknown3 期

The Clinical Effect of i-FACTOR® Versus Allograft in Non-instrumented Posterolateral Spondylodesis Operation

Sygehus Lillebaelt2 个研究点 分布在 1 个国家目标入组 108 人开始时间: 2012年3月1日最近更新:
适应症
干预措施

试验速览

阶段
3 期
发起方
入组人数
108
试验地点
2
主要终点
The clinical effect of i-FACTOR® versus allograft in non-instrumented posterolateral spondylodesis operation in the elderly with spinal stenosis due to degenerative spondylolisthesis measured by ODI

研究概览

简要总结

The average life expectancy in Denmark is increasing resulting in an increasing part of the population having age-related disease, ex lumbar spinal stenosis (LSS). LSS causes constriction of the nerves in the lumbar spine resulting in pain in the legs and lower back, especially when standing and walking, known as neurogenic claudication(Goh KJ FAU - Khalifa et al.). LSS occurs in a combination of degenerative changes in the lower back, including hypertrophy of the ligamentum flavus, arthrosis of the facet joints and bulging of the disc.

Current treatment of LSS is varied ranging from non-operative conservative treatment to operation.

Operative intervention shows very good results according to physical ability and pain(Christensen FB et al.;Hee HT and Wong;McGregor AH FAU - Hughes and Hughes;Xu et al.), but the most optimal treatment is still debated. Nevertheless, a decompression and, if needed, a spinal fusion is recommended.(Ausman).

Clinical improvement including decrease of pain, improved ADL-function and an increased quality of life are parameters of highest interest and the purpose of an operation is clear: Making sufficient room for the affected nerves. In addition fusion is desired achieving stability avoiding a new compression of the nerves. Studies attending these issues find a correlation between fusion and clinical outcome, why obtained fusion of the affected levels are very important(Andersen et al.;Andersen et al.;Girardo et al.;Kornblum MB FAU - Fischgrund et al.).

P-15, bound to Anorganisk Bone Mineral (ABM), called i-FACTOR®, shows fusion superiority, no side effects and no risk of transferring disease(Thorwarth et al. 5648-57;Thorwarth et al. 789-95;Wenz, Oesch, and Horst 1599-606;Scarano et al. 318-24;Kubler et al. 171-79) why the investigators find this material suited for fusion surgery in the elderly.

To the investigators knowledge this is the first prospective study comparing fusion rates and postoperative clinic with i-FACTOR vs allograft in older patients operated with decompression and spondylodesis because of spinal stenosis due to degenerative spondylolisthesis.

Hypothesis:

There are no difference in the clinical parameters measured by ODI and fusion rates comparing i-FACTOR® and allograft in non-instrumented posterolateral spondylodesis-operations in patients 60 years and older.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
60 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Spinal stenosis, olisthesis grade 1-2 (>3 mm), facet joint arthrosis and flavus hypertrophia verified by a mr-scan and x-ray including maximally 2 levels ranging from L1-S
  • •A score of 6 and more on Konno´s "History of Examination Characteristic".
  • •Signed informed content.

排除标准

  • •Any disease demanding obligate thromboprophylaxis treatment, including mechanical valve, (DVT with cancer/thrombophilia, AMI, apoplexia cerebri, TCI, valve-operation)< 3 months, coronar metal stent < 6 weeks and coronar drug eluted/coated stent < 12 months.
  • •Atrial fibrillation and one of the following: Mitral stenosis, valveprothesis and apoplexia cerebri/TCI.
  • •Atrial fibrillation and two of the following: Heart insufficient, HT, DM, age > 75 years, EF < 35 %.
  • •Known cancer in the axial skeleton.
  • •Ongoing chemotherapy.
  • •Fracture i the lower back within a year prior to inclusion.
  • •Reduced distance of walking due to non-spinal related causes.
  • •Candidate for more than two-level intervention.
  • •Dementia assessed by the MMSE
  • •Age below 60 years.
  • •Missed 3 months of conservative treatment without success
  • •The use of steroids and bisphosphonates.
  • •Prior radiotherapy to the lower back.
  • •Haematologic disease.

研究组 & 干预措施

Fusion, allograft

Active Comparator

Allograft used for fusion in the operation site

干预措施: i-FACTOR (Biological)

Fusion, i-FACTOR

Experimental

i-FACTOR used for fusion in the operation site

干预措施: i-FACTOR (Biological)

结局指标

主要结局

The clinical effect of i-FACTOR® versus allograft in non-instrumented posterolateral spondylodesis operation in the elderly with spinal stenosis due to degenerative spondylolisthesis measured by ODI

时间窗: 24 months postoperative

次要结局

  • The clinical effect of i-FACTOR® versus allograft in non-instrumented posterolateral spondylodesis operation in the elderly with spinal stenosis due to degenerative spondylolisthesis assessed by fusion rates(12 months postoperative)

研究者

发起方
Sygehus Lillebaelt
申办方类型
Other
责任方
Principal Investigator
主要研究者

Michael Kjaer Jacobsen

MD

Sygehus Lillebaelt

研究点 (2)

Loading locations...

相似试验

The Clinical Effect of i-FACTOR® Versus Allograft in... | 临床试验